Loading...

PRLD PRELUDE THERAPEUTICS INC Company Mergers 8-K Filing

PRLD

PRLD

PRELUDE THERAPEUTICS INC

(PRLD)

2025 8-K

Financial Results Announced

Exclusive Option Agreement

Compliance Regained

Financial Results Update

Financial Statements

Product Expansion

Financial Results

CFO Appointment

Strategic Partnership

Financial Results

Clinical Data Update

Clinical Data Release

ESMO Announcement

Financial Results

Annual Meeting of Stockholders

Presentation and Educationa...

Appointment and Stock Optio...

Financial Results Announcement

Departure of Chief Financia...

Financial Results Announcement

Securities Purchase Agreement

Financial Results Announcement

Earnings Reports

Annual Meeting Results

Investor Conferences

Entry into a Material Defin...

Financial Results and Inves...

Sales Agreement with Jeffer...

Financial Results and Colla...

Investor Presentation

Amended and Restated Bylaws

Investor Presentation

External Links:

Prelude Therapeutics Inc entered into an Exclusive Option Agreement with Incyte on November 3, 2025, allowing Incyte to potentially acquire Prelude's JAK2V617F inhibitor program for up to $910 million. The deal includes an immediate payment of $60 million and an option for Incyte to purchase the assets for $100 million within 15 months.

AI Assistant

PRELUDE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.